PledPharma : becomes Egetis Therapeutics with a focus on the development of orphan drugs in the late phase

Stockholm - PledPharma AB (publ) (ticker: PLED) announced today that the company has formally changed its name to Egetis Therapeutics AB (publ) (ticker: EGTX).

The decision was made at the Annual General Meeting on December 11, 2020. The name change is a result of the acquisition of Rare Thyroid Therapeutics AB (RTT) and the company's new strategic focus on the development of orphan drugs for rare diseases.

PledPharma announced the acquisition of RTT in early October 2020. In order to clarify the new strategic direction and focus on orphan drugs in the late clinical development phase, it was also announced that the new company will be named Egetis Therapeutics. The name alludes to the company's focus on rare diseases where there are great medical needs and no or few adequate forms of treatment today. Egetis is Latin and means 'You need / miss'. The decision on the name change was formally made at the Annual General Meeting on December 11, 2020.

'With Egetis Therapeutics, we get a name that reflects our focus on rare diseases where there are great medical needs. Our ambition is to build a specialized company for the development of orphan drugs, and with the acquisition of RTT, we already have two orphan drugs in late clinical development with Emcitate and Aladote from the start. The ambition is to build a portfolio of orphan drugs that can potentially improve and change the lives of many patients around the world, 'says Nicklas Westerholm, CEO of Egetis Therapeutics.

Contact:

Nicklas Westerholm

Tel: [phone]

Email: [e-mail]

About Egetis Therapeutics

Egetis is an innovative, unique and integrated drug development company, focused on projects in the late clinical development phase in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Emcitate is a 'first-in-class' drug candidate that is being developed for the treatment of MCT8 deficiency, a rare disease with a great medical need and no treatment available. A Phase IIb clinical trial has been successfully conducted with significant and clinically relevant treatment outcomes. A registration-based intervention study (phase IIb / III) was started in Q4 2020 when the first patient was dosed and interim results are planned for 2022. Emcitate has orphan drug status in the US and Europe and was granted Rare Pediatric Disease status in the US in November 2020. Aladote is a 'first-in-class' drug candidate that is being developed to reduce acute liver damage due to paracetamol poisoning. A proof of principle study has been successfully completed and the design of a registration-based phase II / III study aimed at applying for market approval in the US and EU has been finalized through discussions with the FDA, EMA and MHRA. Aladote has been granted orphan drug status in the United States. Results from the POLAR program announced in December 2020 show that PledOx did not meet the effect measure. Based on further evaluation of the results from the POLAR studies, the next strategic steps for PledOx will be decided together with our partner Solasia. A proof of principle study has been successfully completed and the design of a registration-based phase II / III study with the aim of applying for market approval in the US and the EU has been finalized through discussions with the FDA, EMA and MHRA. Aladote has been granted orphan drug status in the United States. Results from the POLAR program announced in December 2020 show that PledOx did not meet the effect measure. Based on further evaluation of the results from the POLAR studies, the next strategic steps for PledOx will be decided together with our partner Solasia. A proof of principle study has been successfully completed and the design of a registration-based phase II / III study with the aim of applying for market approval in the US and the EU has been finalized through discussions with the FDA, EMA and MHRA. Aladote has been granted orphan drug status in the United States. Results from the POLAR program announced in December 2020 show that PledOx did not meet the effect measure. Based on further evaluation of the results from the POLAR studies, the next strategic steps for PledOx will be decided together with our partner Solasia. Results from the POLAR program announced in December 2020 show that PledOx did not meet the effect measure. Based on further evaluation of the results of the POLAR studies, the next strategic steps for PledOx will be decided together with our partner Solasia. Results from the POLAR program announced in December 2020 show that PledOx did not meet the effect measure. Based on further evaluation of the results of the POLAR studies, the next strategic steps for PledOx will be decided together with our partner Solasia.

(C) 2020 Electronic News Publishing, source ENP Newswire